Downloads: 182

Files in This Item:
File Description SizeFormat 
ar3460.pdf2.33 MBAdobe PDFView/Open
Title: Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability.
Authors: Mitsui, Hiroto
Aoyama, Tomoki  kyouindb  KAKEN_id
Furu, Moritoshi  kyouindb  KAKEN_id
Ito, Kinya
Jin, Yonghui  kyouindb  KAKEN_id
Maruyama, Takayuki
Kanaji, Toshiya
Fujimura, Shinsei
Sugihara, Hikaru
Nishiura, Akio
Otsuka, Takanobu
Nakamura, Takashi
Toguchida, Junya  kyouindb  KAKEN_id
Author's alias: 青山, 朋樹
Keywords: prostaglandin E2
Issue Date: 14-Sep-2011
Publisher: BioMed Central Ltd
Journal title: Arthritis research & therapy
Volume: 13
Thesis number: R146
Abstract: [Introduction]Osteoarthritis (OA) is a common cause of disability in older adults. We have previously reported that an agonist for subtypes EP2 of the prostaglandin E2 receptor (an EP2 agonist) promotes the regeneration of chondral and osteochondral defects. The purpose of the current study is to analyze the effect of this agonist on articular cartilage in a model of traumatic degeneration. [Methods]The model of traumatic degeneration was established through transection of the anterior cruciate ligament and partial resection of the medial meniscus of the rabbits. Rabbits were divided into 5 groups; G-S (sham operation), G-C (no further treatment), G-0, G-80, and G-400 (single intra-articular administration of gelatin hydrogel containing 0, 80, and 400 μg of the specific EP2 agonist, ONO-8815Ly, respectively). Degeneration of the articular cartilage was evaluated at 2 or 12 weeks after the operation. [Results]ONO-8815Ly prevented cartilage degeneration at 2 weeks, which was associated with the inhibition of matrix metalloproteinase-13 (MMP-13) expression. The effect of ONO-8815Ly failed to last, and no effects were observed at 12 weeks after the operation. [Conclusions]Stimulation of prostaglandin E2 (PGE2) via EP2 prevents degeneration of the articular cartilage during the early stages. With a system to deliver it long term, the EP2 agonist could be a new therapeutic tool for OA.
Rights: © 2011 Mitsui et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI(Published Version): 10.1186/ar3460
PubMed ID: 21914215
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.